Regeneron Pharmaceuticals Inc (REGN) Q2 2024 (USD): Adj. EPS 11.56 (exp. 10.61), Revenue 3.55bln (exp. 3.38bln)
Drug Sales
- Dupixent US 2.61bln (exp. 2.57bln).
- Libtayo US 182.4mln (exp. 203.7mln).
- Kevzara US 65.1mln (exp. 58.8mln).
- Evkeeza US 31mln (exp. 24mln).
- Dupixent 3.56bln (exp. 3.43bln).
- Libtayo 297.4mln (exp. 280.3mln).
- Praluent 191.9mln (exp. 174.7mln).
- Kevzara 109.7mln (exp. 100.5mln).
Guidance:
- FY R&D expenses 5.02-5.17bln (prev. 4.92-5.17bln).
- SG&A expense 2.92-3.06bln (prev. 2.94-3.09bln).
01 Aug 2024 - 11:30- Equities- Source: REGN IR
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts